Enveda Biosciences
- Company typePrivate
- Founded2019
- HeadquartersBoulder, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Enveda Biosciences firmographics
Firmographics- Name
- Enveda Biosciences
- Legal name
- Enveda Therapeutics, Inc.
- Website
- https://enveda.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Enveda Biosciences industry classification
Industry- Product category
- Drug Discovery & Development (Natural Product-Derived Pharmaceuticals)
- NAICS
- Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Enveda Biosciences is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Enveda Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharma strategic investment / partnership capital: Strategic equity investments from pharmaceutical partners (e.g., Sanofi's investment in Enveda's Series C, bringing total to $150M) to advance the platform and specific clinical programs to trials. Acts as upfront partnership capital with embedded collaboration rights.
- Venture capital equity funding: Pre-revenue clinical-stage biotech funded primarily through successive equity rounds (Series A led by Lux Capital, B1 led by Kinnevik, C led by Kinnevik/FPV with Sanofi, D led by Premji Invest). Total raised ~$517M. Reaches unicorn status in Sept 2025 at >$1B valuation.
- Future pharma out-licensing and milestone economics: Website contact form explicitly solicits in-licensing and out-licensing inquiries, indicating forward plan to monetize the pipeline of 10+ development candidates via asset-level deals, milestones, and royalties on approved drugs once clinical data validates programs.
Go-to-market motion4 records
Enveda Biosciences product offering
Product offeringCore offering
Enveda Biosciences is a clinical-stage biotechnology company that discovers and develops small-molecule drug candidates derived from natural products, primarily plant sources. The company uses an AI-driven platform that combines mass spectrometry, a proprietary foundation model (PRISM), and the world's largest searchable plant-derived molecule library to identify therapeutic compounds. Its current pipeline includes three clinical-stage assets (ENV-294 for atopic dermatitis and asthma, ENV-308 for obesity, and ENV-6946 for inflammatory bowel disease), six IND-enabling candidates, and 17 development candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- ENV-294 (clinical asset)
- ENV-308 (clinical asset)
- ENV-6946 (clinical asset)
Companies that use Enveda Biosciences
Customer profileIdeal customer profiles2 records
Enveda Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Enveda Biosciences partnerships and signals
Strategic signalScale indicators11 records
Recent moves6 records
Expansion highlights6 records
Enveda Biosciences competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Enveda Biosciences social profiles
Digital presenceEnveda Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enveda Biosciences leadership team
Management profileNumber of profiles
Profiles18 records
Enveda Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Enveda Biosciences funding detail
Funding detailFunding overview
Funding rounds11 records
Investors37 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enveda Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enveda Biosciences
What does Enveda Biosciences do?
Enveda Biosciences is a clinical-stage biotechnology company that discovers and develops small-molecule drug candidates derived from natural products, primarily plant sources. The company uses an AI-driven platform that combines mass spectrometry, a proprietary foundation model (PRISM), and the world's largest searchable plant-derived molecule library to identify therapeutic compounds. Its current pipeline includes three clinical-stage assets (ENV-294 for atopic dermatitis and asthma, ENV-308 for obesity, and ENV-6946 for inflammatory bowel disease), six IND-enabling candidates, and 17 development candidates.
Is Enveda Biosciences a public or private company?
Enveda Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Enveda Biosciences founded?
Enveda Biosciences was founded in 2019. It employs 101 to 250 people.
Where is Enveda Biosciences based?
Enveda Biosciences is headquartered in Boulder, United States, in the North America region.
How does Enveda Biosciences make money?
Three revenue lines are on record. Pharma strategic investment / partnership capital is the primary driver. The others are venture capital equity funding and future pharma out-licensing and milestone economics.
Does Enveda Biosciences have an API?
No public API is recorded for Enveda Biosciences.
What industry is Enveda Biosciences in?
Enveda Biosciences's product category is Drug Discovery & Development (Natural Product-Derived Pharmaceuticals). Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.